고혈압 치료제 시장 : 시장 인사이트, 역학, 시장 예측(-2034년)

Key Highlights:

• Approximately 45% of adults with uncontrolled hypertension exhibit blood pressure readings at or above 140/90 mmHg, indicating a significant burden of poorly managed cases. This translates to an around 37 million individuals in the United States alone, underscoring the widespread prevalence and the urgent need for more effective treatment and monitoring strategies.
• A study conducted in Italy found that 42.3% of adults reported having been diagnosed with hypertension.
• Rising hypertension cases are driven by multiple factors, including sedentary lifestyles, poor dietary habits, obesity, high salt intake, stress, and increased alcohol and tobacco use. Aging populations and genetic predisposition also contribute. Additionally, lack of physical activity and inadequate sleep further elevate risk, making hypertension a growing global health concern.
• The hypertension treatment landscape is evolving with recent Food and Drug Administration (FDA) approvals of innovative therapies like WIDAPLIK (telmisartan, amlodipine, and indapamide) by George Medicines and TRYVIO/ JERAYGO (aprocitentan) by Idorsia Pharmaceuticals. These advanced agents offer improved efficacy, tolerability, and simplified regimens, addressing unmet needs in resistant and uncontrolled hypertension and enhancing patient outcomes through novel mechanisms and combination approaches.
• Leading pharmaceutical companies such as AstraZeneca (baxdrostat), Mineralys Therapeutics (lorundrostat), and Eli Lilly and Company (orforglipron) among others are actively developing innovative hypertension therapies. As these drugs gain FDA approval, they are expected to reshape the treatment paradigm, offering enhanced efficacy and safety. This shift is poised to drive market transition toward these novel agents, generating substantial revenue growth and addressing unmet clinical needs.
• In March 2025, Idorsia reported that the US FDA has eliminated the REMS (Risk Evaluation and Mitigation Strategy) requirement for TRYVIO (aprocitentan), thereby reducing the administrative and logistical burden on healthcare providers and patients.

DelveInsight's comprehensive report titled "Anti-Hypertension - Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of anti-hypertension. The report presents historical and projected epidemiological data covering prevalent cases of hypertension, diagnosed prevalent cases of hypertension, gender-specific diagnosed prevalent cases of hypertension and age-specific diagnosed prevalent cases of hypertension. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across 7MM: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in anti-hypertension. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Anti-Hypertension Overview

Hypertension, or systemic arterial hypertension, is defined by consistently elevated blood pressure within the systemic arteries. Blood pressure is typically measured as a ratio of systolic pressure-when the heart contracts-and diastolic pressure-when the heart relaxes. It is the most prevalent modifiable risk factor for cardiovascular diseases (CVD) such as coronary artery disease, stroke, heart failure, myocardial infarction, atrial fibrillation, and peripheral artery disease. Additionally, hypertension contributes significantly to chronic kidney disease, cognitive decline, and remains the leading global cause of death and disability. Risk factors for developing high blood pressure include advancing age, genetic predisposition, obesity, physical inactivity, excessive salt intake, and heavy alcohol consumption. Individuals with severely elevated blood pressure (typically 180/120 mmHg or higher) may experience acute symptoms such as intense headaches, chest pain, dizziness, shortness of breath, nausea, vomiting, blurred vision, anxiety, confusion, tinnitus, nosebleeds, and irregular heart rhythms, requiring immediate medical attention.

Anti-Hypertension Diagnosis and Treatment Overview

Diagnosing hypertension involves more than identifying elevated blood pressure-it requires evaluating cardiovascular risk, detecting target organ damage, and identifying coexisting conditions that may influence blood pressure or organ health. Clinicians also assess for signs of secondary hypertension, which may arise from underlying causes. Lifestyle modifications are foundational in managing hypertension. These include adopting a low-sodium, heart-healthy diet, engaging in regular physical activity, achieving a healthy weight, and quitting tobacco use. When lifestyle changes are insufficient, medication may be prescribed. Blood pressure targets vary: individuals with cardiovascular disease, diabetes, chronic kidney disease, or high CVD risk should aim for readings below 130/80 mmHg, while others should maintain levels under 140/90 mmHg. Common antihypertensive drugs include ACE inhibitors (e.g., enalapril, lisinopril) and ARBs (e.g., losartan, telmisartan), which relax blood vessels and protect kidneys; calcium channel blockers (e.g., amlodipine) that ease vessel tension; and diuretics (e.g., hydrochlorothiazide) that reduce fluid volume.

Anti-Hypertension Epidemiology

The epidemiology section of the anti-hypertension market report offers information on the patient populations, including historical and projected trends for each of the 7MM. Examining Key Opinion Leader (KOL) views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of anti-hypertension. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

• According to secondary data from the Centers for Disease Control and Prevention (CDC), approximately 48.1% of adults in the United States are affected by high blood pressure. This figure highlights the widespread nature of hypertension.
• Secondary analysis reveals that 29.3% of the population in Germany is affected by hypertension. This prevalence rate underscores the substantial burden of high blood pressure within the country, indicating a critical need for ongoing public health efforts focused on early detection, lifestyle modification, and effective clinical management.
• CDC data suggest that hypertension is more frequently reported in males than in females in the US; however, among females, the condition still represents a substantial burden, accounting for approximately 44% of all reported cases by gender.
• According to secondary analysis, in Japan, nearly 70% of hypertension cases are reported among males aged 70 years and above, indicating a higher prevalence in this age group compared to younger populations.

Anti-Hypertension Market Outlook

The anti-hypertension therapeutics market is further expected to increase by the major drivers, such as the rising prevalent population, technological advancements, and upcoming therapies in the forecast period (2025-2034).

The treatment landscape for hypertension is undergoing a transformative shift, driven by innovation, unmet clinical needs, and evolving patient expectations. Traditional therapies, including Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin II Receptor Blockers (ARBs), beta-blockers, calcium channel blockers, and diuretics, remain foundational. However, resistant and uncontrolled hypertension continues to challenge clinicians, prompting the development of novel agents. Recently approved drugs like WIDAPLIK by George Medicines, TRYVIO/ JERAYGO (aprocitentan) by Idorsia Pharmaceuticals offer new mechanisms targeting endothelin pathways, providing options for patients unresponsive to standard regimens.

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the anti-hypertension market in the 7MM is expected to change significantly during the forecast period (2025-2034).

Anti-Hypertension Drug Chapters

Marketed Drugs

WIDAPLIK (telmisartan, amlodipine and indapamide): George Medicines

WIDAPLIK is a fixed-dose combination tablet containing telmisartan (ARBs), amlodipine (a dihydropyridine calcium channel blocker), and indapamide (a thiazide-like diuretic). It is available in various dosage strengths. WIDAPLIK is indicated for the management of hypertension, including use as an initial therapy, with the primary goal of reducing blood pressure and carries a Boxed Warning for fetal toxicity.

• In July 2025, George Medicines reported that it had entered into an exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK (a fixed-dose combination of telmisartan, amlodipine, and indapamide) tablets in the United States.
• In June 2025, George Medicines reported that the US FDA has granted approval for WIDAPLIK previously referred to as "GMRx2," for the treatment of hypertension in adults, including as an initial therapy aimed at lowering blood pressure.

TRYVIO/ JERAYGO (aprocitentan): Idorsia Pharmaceuticals

TRYVIO/ JERAYGO is a once-daily oral medication developed by Idorsia Pharmaceuticals, designed as a dual endothelin A (ETA) and B (ETB) receptor antagonist for the treatment of hypertension. The endothelin signaling pathway plays a key role in the pathophysiology of hypertension. Aprocitentan, the active component, blocks the interaction of endothelin-1 with ETA and ETB receptors, thereby mitigating its harmful effects and contributing to blood pressure reduction and European Commission (EC) has approved JERAYGO (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.

• In March 2024, Idorsia reported that the US FDA has approved TRYVIO (aprocitentan) for the treatment of hypertension in adults whose blood pressure is not adequately controlled with existing therapies. The approval supports its use in combination with other antihypertensive agents to achieve blood pressure reduction.

Emerging Drugs

Baxdrostat: AstraZeneca

Baxdrostat (also known as CIN-107), is an investigational, first-in-class oral small molecule that selectively and potently inhibits aldosterone synthase, an enzyme encoded by the CYP11B2 gene and responsible for aldosterone production in the adrenal gland. Clinical trials have shown that baxdrostat effectively reduces aldosterone levels across various doses without impacting cortisol levels. It is currently being studied as a monotherapy for the treatment of hypertension.

• In July 2025, AstraZeneca reported that Baxdrostat successfully achieved both the primary and all secondary endpoints in the BaxHTN Phase III trial, conducted in patients with uncontrolled or treatment-resistant hypertension.
• In February 2023, AstraZeneca completed its acquisition of CinCor Pharma, a US clinical-stage biopharma company developing therapies for resistant hypertension and chronic kidney disease. The deal strengthens AstraZeneca's cardiorenal pipeline by adding baxdrostat (CIN-107), an aldosterone synthase inhibitor aimed at lowering blood pressure in treatment-resistant hypertension.

Lorundrostat: Mineralys Therapeutics

Lorundrostat is a proprietary, oral aldosterone synthase inhibitor under development for treating uncontrolled or resistant hypertension. It targets CYP11B2, the enzyme responsible for aldosterone production, and exhibits 374-fold selectivity over cortisol synthase in vitro. With a half-life of 10-12 hours, lorundrostat has shown a 40-70% reduction in plasma aldosterone levels in hypertensive patients.

• In June 2025, Mineralys Therapeutics reported the publication of positive results from its pivotal Phase III Launch-HTN trial in the Journal of the American Medical Association (JAMA).

Orforglipron: Eli Lilly and Company

Orforglipron (LY3502970) is an investigational, once-daily oral small molecule GLP-1 receptor agonist that is non-peptide in nature and can be taken at any time, with no restrictions on food or water intake. Originally discovered by Chugai Pharmaceutical. and licensed to Lilly in 2018, both companies jointly published its preclinical pharmacology data.

• Eli Lilly is currently conducting Phase III trials to evaluate orforglipron for the treatment of hypertension.

Anti-Hypertension Market Segmentation

DelveInsight's 'Anti-Hypertension - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a detailed outlook of the current and future anti-hypertension market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Anti-Hypertension Market Size by Countries

The anti-hypertension market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. In 2024, the United States held a significant share of the overall 7MM anti-hypertension market, primarily attributed to the country's higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Anti-Hypertension Market Size by Therapies

Anti-hypertension market size by therapies is categorized into current and emerging markets for the study period 2020-2034.

Anti-Hypertension Drugs Uptake

This section focuses on the sales uptake of potential anti-hypertension drugs that have recently been launched or are anticipated to be launched in the anti-hypertension market between 2020 and 2034. It estimates the market penetration of anti-hypertension drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the anti-hypertension market.

The emerging anti-hypertension therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the anti-hypertension market.

Anti-Hypertension Market Access and Reimbursement

DelveInsight's 'Anti-Hypertension - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a descriptive overview of the market access and reimbursement scenario of anti-hypertension. This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

Key Opinion Leader (KOL) Views

To keep up with current anti-hypertension market trends and fill gaps in secondary findings, we interview KOLs and SMEs' working in the anti-hypertension domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or anti-hypertension market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the anti-hypertension unmet needs.

Anti-Hypertension: KOL Insights

DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as, CDC, National Center for Chronic Disease Prevention and Health Promotion, US, Institut fur Pharmakookonomie und Arzneimittellogistik (IPAM), Wismar, MV, Germany; Hospices Civils De Lyon and University of Lyon, Lyon, France; University of L'Aquila, Building Delta 6, Coppito, 67100 L'Aquila, Italy; Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; University of Sheffield, UK; Department of Public Health, Shiga University of Medical Science, Otsu, Japan, among others.

"As per KOL from the US, "Data indicate that blood pressure control in most hypertension patients is achieved through the use of two or more medications. WIDAPLIK is being positioned as an alternative approach for managing hypertension, including in treatment-naive individuals. Its triple combination efficacy, proven safety, favorable tolerability, and single-pill formulation are viewed as potential solutions to key challenges in existing hypertension treatment strategies."

"As per KOL from the UK, "lifestyle modifications-including smoking cessation, reduced alcohol intake, and improvements in diet and exercise-should be encouraged in individuals with untreated white coat hypertension. Caution is advised against over-treatment of those already receiving blood pressure medication, as this may result in dangerously low blood pressures outside the clinical setting and unnecessary medication-related side effects."

"As per KOL from Japan, "Despite available treatments, hypertension remains poorly controlled in many patients due to complex regimens, side effects, and low adherence. A significant unmet need exists for simplified, effective therapies that offer sustained blood pressure control, improved tolerability, and enhanced patient compliance to reduce cardiovascular risks and long-term complications."

Competitive Intelligence Analysis

We conduct a competitive and market intelligence analysis of the anti-hypertension. Market, utilizing various competitive intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Anti-Hypertension Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for anti-hypertension. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging anti-hypertension therapies.

Anti-Hypertension Report Insights

• Anti-Hypertension Patient Population
• Therapeutic Approaches
• Anti-Hypertension Pipeline Analysis
• Anti-Hypertension Market Size and Trends
• Anti-Hypertension Market Opportunities
• Impact of Upcoming Therapies

Anti-Hypertension Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Anti-Hypertension Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Anti-Hypertension Market
• Anti-Hypertension Drugs Uptake

Anti-Hypertension Report Assessment

• Anti-Hypertension Current Treatment Practices
• Unmet Needs
• Anti-Hypertension Product Profiles
• Anti-Hypertension Market Attractiveness

Key Questions:

• How common is anti-hypertension?
• What are the key findings of anti-hypertension epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020-2034)?
• What are the currently available treatments for anti-hypertension?
• What are the disease risk, burden, and unmet needs of anti-hypertension?
• At what CAGR is the anti-hypertension market and its epidemiology is expected to grow in the 7MM during the forecast period (2025-2034)?
• How would the unmet needs impact the anti-hypertension market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of anti-hypertension in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025-2034)?
• How many companies are currently developing therapies for the treatment of anti-hypertension?

Reasons to buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the anti-hypertension market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• Highlights of market access and reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of KOL around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What are the treatment goals for anti-hypertension?

The primary treatment goals for antihypertension are to reduce elevated blood pressure to target levels, typically below 130/80 mmHg, to lower the risk of cardiovascular events, stroke, and kidney disease. Achieving sustained blood pressure control, minimizing side effects, and improving patient adherence are essential. Treatment also aims to prevent end-organ damage, enhance quality of life, and address underlying risk factors through lifestyle modifications and appropriate pharmacologic therapy.

2. What are the challenges in managing anti-hypertension?

Managing antihypertension presents several challenges, including poor patient adherence due to complex medication regimens and side effects, variability in individual response to therapy, and difficulty achieving target blood pressure levels. White coat hypertension and masked hypertension complicate diagnosis and monitoring. Limited access to care, inadequate lifestyle changes, and comorbid conditions further hinder effective management. Ensuring long-term control and preventing complications requires personalized, sustained, and multifaceted approaches.

3. What are the key factors driving the growth of the anti-hypertension market?

Key factors driving the growth of the antihypertension market include rising prevalence of hypertension due to aging populations and lifestyle changes, increased awareness and screening efforts, and advancements in combination therapies that improve efficacy and adherence. Government initiatives and healthcare investments support early diagnosis and treatment. Additionally, innovations in drug formulations, such as single-pill combinations, and growing demand for personalized medicine contribute to market expansion and improved patient outcomes.

4. How will the anti-hypertension market and epidemiology forecast report benefit the clients?

The anti-hypertension market and epidemiology forecast report offers clients strategic insights into disease prevalence, patient segmentation, and market dynamics. It helps identify commercial opportunities, assess treatment gaps, and support planning for product development, market entry, or expansion. The report also aids stakeholders in understanding regulatory landscapes, forecasting trends, and making data-driven investment or policy decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Anti-Hypertension Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Anti-Hypertension by Therapies in the 7MM in 2024
• 3.2. Market Share (%) Distribution of Anti-Hypertension by Therapies in the 7MM in 2034

4. Epidemiology and Market Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Types
• 7.3. Causes
• 7.4. Pathophysiology
• 7.5. Symptoms
• 7.6. Risk Factor
• 7.7. Diagnosis
  • 7.7.1. Diagnostic Algorithm
  • 7.7.2. Diagnostic Guidelines
• 7.8. Treatment and Management
  • 7.8.1. Treatment Algorithm
  • 7.8.2. Treatment Guidelines

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale:7MM
• 8.3. Diagnosed Prevalent Cases of Hypertension in the 7MM
• 8.4. The United States
  • 8.4.1. Prevalent Cases of Hypertension
  • 8.4.2. Diagnosed Prevalent Cases of Hypertension
  • 8.4.3. Gender-specific Diagnosed Prevalent Cases of Hypertension
  • 8.4.4. Age-specific Diagnosed Prevalent Cases of Hypertension
• 8.5. EU4 and the UK
  • 8.5.1. Prevalent Cases of Hypertension
  • 8.5.2. Diagnosed Prevalent Cases of Hypertension
  • 8.5.3. Gender-specific Diagnosed Prevalent Cases of Hypertension
  • 8.5.4. Age-specific Diagnosed Prevalent Cases of Hypertension
• 8.6. Japan
  • 8.6.1. Prevalent Cases of Hypertension
  • 8.6.2. Diagnosed Prevalent Cases of Hypertension
  • 8.6.3. Gender-specific Diagnosed Prevalent Cases of Hypertension
  • 8.6.4. Age-specific Diagnosed Prevalent Cases of Hypertension

9. Patient Journey

10. Marketed Therapies

• 10.1. Key Cross Competition
• 10.2. WIDAPLIK (telmisartan, amlodipine and indapamide): George Medicines
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Development Activities
  • 10.2.4. Clinical Trials Information
  • 10.2.5. Safety and Efficacy
• 10.3. TRYVIO/ JERAYGO (aprocitentan): Idorsia Pharmaceuticals
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Other Development Activities
  • 10.3.4. Clinical Trials Information
  • 10.3.5. Safety and Efficacy

11. Emerging Therapies

• 11.1. Key Cross Competition
• 11.2. Baxdrostat: AstraZeneca
  • 11.2.1. Drug Description
  • 11.2.2. Other Development Activities
  • 11.2.3. Clinical Trials Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analyst's View
• 11.3. Lorundrostat: Mineralys Therapeutics
  • 11.3.1. Drug Description
  • 11.3.2. Other Development Activities
  • 11.3.3. Clinical Trials Information
  • 11.3.4. Safety and Efficacy
  • 11.3.5. Analyst's View
• 11.3. Orforglipron: Eli Lilly and Company
  • 11.3.1. Drug Description
  • 11.3.2. Other Development Activities
  • 11.3.3. Clinical Trials Information
  • 11.3.4. Safety and Efficacy
  • 11.3.5. Analyst's View

12. Anti-Hypertension: Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Attribute Analysis
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions and Rebates
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptake
• 12.5. Total Market Size of Anti-Hypertension in the 7MM
• 12.6. Market Size of Anti-Hypertension by Therapies in the 7MM
• 12.7. The United States Market Size
  • 12.7.1. Total Market Size of Anti-Hypertension
  • 12.7.2. Market Size of Anti-Hypertension by Therapies in the US
• 12.8. EU4 and the UK Market Size
  • 12.8.1. Total Market Size of Anti-Hypertension
  • 12.8.2. Market Size of Anti-Hypertension by Therapies in EU4 and the UK
• 12.9. Japan Market Size
  • 12.9.1. Total Market Size of Anti-Hypertension
  • 12.9.2. Market Size of Anti-Hypertension by Therapies in Japan

13. Key Opinion Leaders' Views

14. Unmet Needs

15. SWOT Analysis

16. Market Access and Reimbursement

17. Appendix

• 17.1. Bibliography
• 17.2. Abbreviations and Acronyms
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight